Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting

- Interim results show sustained reduction in hereditary angioedema attacks and no new safety signals in patients treated for one year CARLSBAD, Calif., Nov. 13, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a Phase 2 open-label extension (OLE) study evaluating the safety and efficacy of its investigational antisense medicine, donidalorsen, in patients with hereditary angioedema (HAE), a rare and devastating inflammatory disease. Interim data after all patients completed 1 year of treatment in the study showed a sustained reduction in HAE attacks and no new safety signals following treatment with donidalorsen. Treatment with donidalorsen resulted in an overall sustained mean reduction in HAE attack rates of 95% from baseline. For patients treated with donidalorsen, 99.6% of study days were HAE attack-free.

The release as fetched from its publisher. ionis.com ↗